The main purpose of this document is to provide guidance on how to ensure that the
information on the labelling and package leaflet is accessible to and can be understood by
those who receive it, so that they can use their medicine safely and appropriately.
This guideline is written to assist applicants and marketing authorisations holders when
drawing up the labelling and package leaflet and preparing the mock-ups or specimens of
the sales presentations2
.
The guidance gives advice on the presentation of the content of the labelling and package
leaflet (required in accordance with Title V of the Directive) and on the design and layout
concepts which will aid the production of quality information. It includes guidance on
consultations with target patient groups for the package leaflet.
The guideline also includes information on how the requirements for Braille can be met, as
well as how to make the package leaflet available in formats suitable for the blind and
partially-sighted patients.
Finally, the guideline includes an example of a way of undertaking a test of a package
leaflet.
This guideline is published in accordance with Article 65(c) of Directive 2001/83/EC,
which provides for the development of guidelines concerning the legibility of particulars
on the labelling and package leaflet.
The guideline is intended to apply to all marketing authorisation procedures and to all
medicinal products, including those available without prescription.